Prostate cancer: the United States accelerated a review of a promising treatment

On Tuesday the German laboratory Bayer said that the U.S. Federal Drug Agency (FDA) would consider in a simplified application for authorization of treatment of prostate cancer that develops with the Norwegian Algete.

This is a new hope for the best treatment for prostate cancer, which remains a leading cause of death among men in the world. Indeed, two laboratories, Bayer of Germany and Norway Algete managed to develop a new drug called Alpharadin, or radium-233 chloride with very promising results. At the end of Phase III clinical trials on a large scale, they were able to extend the life of patients with prostate cancer for 14 months against 11.2 months on average for patients with placebo.

The results were so convincing that independent evaluation committee decided to shorten the test phase of the drug Alpharadin a year to provide treatment to all patients studied, including those taking a placebo, said in a statement Algete laboratory.

A procedure applied in very special cases and particularly where the drug can be used to treat serious or life-threatening conditions. This is the case here according to Kemal Malik, a leader of the branch pharmacy group Bayer said, “patients who are at an advanced stage of disease urgently need new treatment options.” A request for authorization should be sent to the market in 2012.

Share and Enjoy

  • Facebook
  • Twitter
  • Delicious
  • LinkedIn
  • StumbleUpon
  • Add to favorites
  • Email
  • RSS